Jed Lampe | iPSC-Derived Fetal/Neonatal Hepatocyte Model | MPRINT 2026 | Day 3

An iPSC-Derived, Metabolically Competent Fetal/Neonatal Hepatocyte-like Cell Model to Study Xenobiotic Metabolism and Toxicity Presented by Jed Lampe, PhD Associate Professor, Department of Pharmaceutical Sciences University of Colorado Recorded 4/15/2026 at the 2026 MPRINT Annual Meeting. In this presentation, Dr. Jed Lampe discusses the development of an induced pluripotent stem cell (iPSC)-derived fetal and neonatal hepatocyte-like cell model designed to improve the study of drug metabolism and toxicity during early life. Neonates and infants exhibit unique physiology and developmental patterns that can substantially alter drug disposition, yet mechanistic studies remain limited by the scarcity of primary fetal and neonatal liver tissue. Dr. Lampe reviews key developmental differences in hepatic drug metabolism and highlights the challenges associated with predicting xenobiotic exposure and toxicity in newborns. He discusses how age-dependent expression of drug-metabolizing enzymes and transporters can influence therapeutic efficacy and adverse drug responses in pediatric populations. The presentation describes efforts to differentiate human iPSCs into metabolically competent hepatocyte-like cells that recapitulate characteristics of fetal and neonatal liver tissue. Dr. Lampe presents data evaluating cellular maturation, expression of developmental liver markers, metabolic enzyme activity, and functional responses to xenobiotic exposure. These models provide a renewable and scalable platform for investigating developmental pharmacology and toxicology. Dr. Lampe also discusses applications of the model for studying drug metabolism pathways, developmental toxicity, and precision medicine approaches in neonatal populations. The work supports the development of more physiologically relevant systems for evaluating medication safety and improving translational research in pediatric clinical pharmacology. About MPRINT: The Indiana CTSI Pharmacometric Modeling and Simulation Program and Maternal Pediatric Precision in Therapeutics Hub (MPRINT Hub) supports collaboration, education, and research in pharmacometrics, model-informed drug development, translational science, and clinical pharmacology. Conference details: Event: MPRINT Annual Meeting 2026 Day: 3 Date: April 15, 2026 Location: Hine Hall, Indianapolis, IN Chapters: 00:00 Introduction and speaker introduction 01:01 Motivation for neonatal liver models 01:40 Developmental differences in infant physiology 02:36 Challenges studying neonatal drug metabolism 03:28 Induced pluripotent stem cells overview 04:21 Generating hepatocyte-like cells 05:37 Developmental liver biology 06:54 Characterization of fetal and neonatal phenotypes 08:22 Drug-metabolizing enzyme expression 09:41 Functional metabolism studies 11:08 Xenobiotic toxicity assessment 12:36 Model validation 13:58 Applications in pediatric pharmacology 15:12 Future directions 16:02 Conclusions and acknowledgments Accessibility: Captions/subtitles are available for this video. Disclaimer: The views and opinions expressed in this presentation are those of the speaker and do not necessarily reflect those of the University of Colorado, Indiana University, Purdue University, the Indiana CTSI, or affiliated organizations.